Skinvisible Inc.

Skinvisible, Inc. (OTC: SKVI) is a pharmaceutical technology company that has developed Invisicare — a proprietary polymer-based transdermal and topical drug delivery technology platform that enhances the ability of active pharmaceutical ingredients to penetrate the skin barrier and achieve localized or systemic drug delivery through topical application. According to its website at skinvisible.com, the Invisicare platform consists of polymer formulations that create an invisible, flexible coating on the skin surface when applied, enabling controlled, sustained release of incorporated active pharmaceutical ingredients over extended periods from a single topical application. The technology's drug delivery enhancement capabilities apply to a broad range of pharmaceutical actives including hormones, NSAIDs, antifungals, and other drugs where sustained topical or transdermal delivery provides clinical advantages over conventional oral or standard topical formulations.

Skinvisible's Invisicare technology, described at skinvisible.com, addresses the significant pharmaceutical formulation challenge of delivering active drugs through the skin's barrier function at therapeutically effective rates and durations — a challenge that limits the effectiveness of conventional topical formulations and drives demand for advanced drug delivery technologies that can improve skin penetration, residence time, and controlled release characteristics of topically applied pharmaceuticals. The Invisicare polymer system's film-forming properties enable formulations that adhere to the skin surface, resist wash-off, and release incorporated actives over hours rather than minutes — providing both improved drug delivery performance and enhanced patient convenience through less frequent dosing compared to standard topical products. Skinvisible licenses its Invisicare technology to pharmaceutical companies and over-the-counter product developers seeking to enhance the performance of their topical formulations.

Skinvisible pursues the commercialization of Invisicare technology through pharmaceutical licensing agreements with drug developers and manufacturers who incorporate the technology into their proprietary topical pharmaceutical formulations, generating royalty revenues from licensed Invisicare products as they reach commercial markets. According to skinvisible.com, the company's licensing strategy targets both prescription pharmaceutical applications — where Invisicare can provide meaningful clinical differentiation for branded topical drug products — and over-the-counter applications where the technology's performance advantages can support premium positioning of consumer healthcare products. Skinvisible's combination of Invisicare transdermal drug delivery technology, pharmaceutical licensing business model, broad active ingredient applicability, OTC-listed public company structure, and royalty revenue generation approach reflects its positioning as a specialty pharmaceutical technology licensor in the topical and transdermal drug delivery market.